

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 10-Q/A**  
Amendment #1

(Mark One)

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

**For the quarterly period ended September 30, 2008**

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from \_\_\_\_\_ to \_\_\_\_\_

COMMISSION FILE NUMBER: 333-101420

**ANTICUS INTERNATIONAL CORPORATION**

(Exact name of small business issuer as specified in its charter)

Nevada

(State or other jurisdiction of incorporation or organization)

98-0375504

(IRS Employer Identification No.)

1155 Rene-Levesque Quest, Suite 2500  
Montreal, Quebec, Canada H3B 2K4  
(514) 992-1391

(Address of principal executive offices)

\_\_\_\_\_  
(Former name, former address and former fiscal year, if changed since last report)

☒ Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company; as defined within Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer   ☐ Accelerated filer   ☐ Non-accelerated filer   ☒ Smaller reporting company

☐ Indicate by check whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

The number of shares outstanding of each of the issuer's classes of common equity as of September 30, 2008:  
45,311,627 shares of common stock

ANTICUS INTERNATIONAL CORPORATION  
(A COMPANY IN THE DEVELOPMENT STAGE)

Contents

	<u>Page Number</u>
PART I FINANCIAL INFORMATION	
Item 1 Interim Financial Statements September 30, 2008	
Interim Balance Sheet	3
Interim Statement of Stockholder's Equity	4
Interim Statement of Operations	7
Interim Statement of Cash Flows	8
Notes to the Interim Financial Statements	9
Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3 Quantitative and Qualitative Disclosures About Market Risk	14
Item 4T Controls and Procedures	14
Part II OTHER INFORMATION	
Item 1 Legal Proceedings	16
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds	16
Item 3 Defaults Upon Senior Securities	16
Item 4 Submission of Matters to a Vote of Security Holders	16
Item 5 Other Information	16
Item 6 Exhibits	16
SIGNATURES	17

*Explanatory Note:*

*On November 13, 2008, the Registrant filed its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2008 (the "Form 10-Q"). The Registrant is filing this Amendment No. 1 to the Form 10-Q ("Amendment No. 1") solely to revise, reformat and correct certain disclosure included in the Form 10-Q. Specifically, the "Controls and Procedures" section was revised in its entirety for clarity and to be more concise. As required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications of our principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, are filed as exhibits to Amendment No. 1.*

*Other than as set forth above, Amendment No. 1 does not modify or update any of the other disclosure contained in the Form 10-Q and does not reflect events occurring after the filing of the Form 10-Q on November 13, 2008.*

ANTICUS INTERNATIONAL CORPORATION  
(A COMPANY IN THE DEVELOPMENT STAGE)

Interim Balance Sheet  
September 30, 2008  
(Expressed in U.S. Funds)  
(Unaudited)

	September 30, 2008 (Unaudited)	June 30, 2008
<b>Assets</b>		
Current assets:		
Cash	\$ 33,788	\$ 19,238
Prepaid expenses	41,364	27,909
Receivable from taxing authorities	<u>28,407</u>	<u>23,867</u>
Total current assets	<u>103,559</u>	<u>71,014</u>
Deferred loan fees, net	8,855	10,366
Intangible asset	374,136	410,736
Laboratory equipment	2,840	3,125
Web site development	<u>11,502</u>	<u>13,010</u>
	<u>397,333</u>	<u>437,237</u>
Total assets	<u>\$ 500,893</u>	<u>\$ 508,251</u>
<b>Liabilities and Stockholders' Equity</b>		
Current liabilities:		
Accounts payable and accrued expenses	\$ <u>45,562</u>	\$ <u>34,010</u>
Total current liabilities	45,562	34,010
Convertible debenture including accrued interest	<u>208,416</u>	<u>204,362</u>
Total liabilities	<u>253,979</u>	<u>238,372</u>
Stockholders' equity:		
Authorized common stock, 75,000,000 shares, \$.001 par value;		
Issued and outstanding:		
45,311,627 shares at September 30, 2008, and	143,645	
43,644,960 shares at June 30, 2008		43,645
Additional paid-in capital	2,128,615	2,128,615
Deficit accumulated during development stage	(2,023,974)	(1,901,496)
Other comprehensive income	<u>(1,372)</u>	<u>(885)</u>
Total stockholders' equity	<u>246,914</u>	<u>269,879</u>
Total liabilities and shareholders' equity	<u>\$ 500,893</u>	<u>\$ 508,251</u>

See notes to financial statements.

ANTICUS INTERNATIONAL CORPORATION  
(A COMPANY IN THE DEVELOPMENT STAGE)

Interim Statement of Stockholder's Equity  
From May 1, 2002 (inception) to September 30, 2008  
(Expressed in U.S. Funds)  
(Unaudited)

	Price Per Share	Common Stock Shares	Amount	Additional Paid-In Capital	Deficit Accumulated During Development Stage	Comprehensive Gain (Loss)	Total Stockholders' Equity (Deficit)
Inception, May 1, 2002	-	-	\$ -	\$ -	\$ -	\$ -	\$ -
Shares issued for cash at \$0.001	\$ 0.0001	9,000,000	9,000	(8,000)	-	-	1,000
Net loss for the period		-	-	-	(1,013)	-	(1,013)
<b>Balance June 30, 2002</b>		9,000,000	9,000	(8,000)	(1,013)	-	(13)
July 15, 2002							
Shares issued for cash at \$0.01	0.0011	14,400,000	14,400	1,600	-	-	16,000
Net loss for the year		-	-	-	(17,250)	-	(17,250)
<b>Balance June 30, 2003</b>		23,400,000	23,400	(6,400)	(18,263)	-	(1,263)
March 31, 2004							
Shares issued for cash at \$0.01	0.0111	450,000	450	4,550	-	-	5,000
May 31, 2004							
Shares issued for cash at \$0.01	0.0111	6,300,000	6,300	63,700	-	-	70,000
Net loss for the year		-	-	-	(38,587)	-	(38,587)
<b>Balance June 30, 2004</b>		30,150,000	30,150	61,850	(56,850)	-	35,150
Cancellation of debt		-	-	115,000	-	-	115,000
Net loss for the year		-	-	-	(198,374)	-	(198,374)
<b>Balance June 30, 2005</b>		30,150,000	30,150	176,850	(255,224)	-	(48,224)
July 1, 2005							
Shares issued for services*	0.0252	924,265	924	22,385	-	-	23,309
July 12, 2005							
Shares issued for services*	0.1200	50,000	50	5,950	-	-	6,000
July 19, 2005							
Shares issued for services*	0.2000	66,286	66	13,191	-	-	13,257
July 27, 2005							
Shares issued for services*	0.2500	52,669	53	13,115	-	-	13,168
July 28, 2005							
Shares issued for license agreement*	0.2400	100,000	100	23,900	-	-	24,000
September 2, 2005							
Shares issued for license agreement*	0.2600	200,000	200	51,800	-	-	52,000
September 7, 2005							
Shares issued for services*	0.2600	228,872	229	59,278	-	-	59,507
October 18, 2005							
Shares issued for services*	0.1700	171,872	172	29,046	-	-	29,218
October 25, 2005							
Recognition of compensation on option grants		-	-	4,850	-	-	4,850
January 23, 2006							
Recognition of compensation on option grants		-	-	7,830	-	-	7,830
January 27, 2006							
Shares issued for services*	0.0850	172,765	173	14,512	-	-	14,685
January 30, 2006							
Shares issued for services*	0.0900	200,000	200	17,800	-	-	18,000

\*See Note 4(b)

See notes to financial statements.

ANTICUS INTERNATIONAL CORPORATION  
(A COMPANY IN THE DEVELOPMENT STAGE)

Interim Statement of Stockholder's Equity  
From May 1, 2002 (inception) to September 30, 2008  
(Expressed in U.S. Funds)  
(Unaudited)

	Price Per Share	Common Stock Shares	Amount	Additional Paid-In Capital	Deficit Accumulated During Development Stage	Comprehensive Gain (Loss)	Total Stockholders' Equity (Deficit)
April 18, 2006							
Shares issued for services*	0.18	227,500	228	40,722	-	-	40,950
April 19, 2006							
Recognition of compensation on option grants		-	-	14,030	-	-	14,030
April 20, 2006							
Shares issued for license agreement*	0.20	2,310,000	2,310	459,690	-	-	462,000
May 31, 2006							
Shares issued for cash*	0.25	500,000	500	124,500	-	-	125,000
June 12, 2006							
Shares issued for cash*	0.25	100,000	100	25,900	-	-	25,000
June 15, 2006							
Shares issued for cash*	0.25	45,000	45	11,586	-	-	11,631
Estimated value of rent charged to operations		-	-	3,600	-	-	3,600
Estimated value of services charged to operations		-	-	10,000	-	-	10,000
Comprehensive gain		-	-	-	-	29	29
Net loss for the year		-	-	-	(412,544)	-	(412,544)
<b>Balance, June 30, 2006</b>		35,499,229	\$ 35,499	\$ 1,129,535	\$ (667,768)	\$ 29	\$ 497,295
August 14, 2006							
Shares issued for services	0.23	75,016	75	18,679	-	-	18,754
August 17, 2006							
Shares issued for cash	0.25	100,000	100	24,900	-	-	25,000
August 21, 2006							
Shares issued for services*	0.24	125,000	125	29,875	-	-	30,000
August 31, 2006							
Shares issued for cash*	0.25	60,000	60	14,940	-	-	55,000
October 3, 2006							
Shares issued for license agreement*	0.18	1,500,000	1,500	268,500	-	-	270,000
May 28, 2007							
Shares issued for cash*	0.07	5,714,286	5,715	399,336	-	-	405,051
Offering costs			-	(36,153)			(36,153)
Recognition of compensation on option grants							
October 3, 2006		-	-	6,405	-	-	6,405
December 15, 2006		-	-	22,550	-	-	22,550
March 15, 2007		-	-	22,550	-	-	22,550
June 15, 2007		-	-	22,550	-	-	22,550
Comprehensive gain		-	-	-	-	2,658	2,658
Net loss for the period		-	-	-	(529,227)	-	(529,227)
<b>Balance, June 30, 2007</b>		43,073,531	\$ 43,074	\$ 1,923,667	\$ (1,196,995)	\$ 2,687	\$ 772,433

\*See Note 4(b)

See notes to financial statements.

ANTICUS INTERNATIONAL CORPORATION  
(A COMPANY IN THE DEVELOPMENT STAGE)

Interim Statement of Stockholder's Equity  
From May 1, 2002 (inception) to September 30, 2008  
(Expressed in U.S. Funds)  
(Unaudited)

	Price Per Share	Common Stock Shares	Amount	Additional Paid-In Capital	Deficit Accumulated During Development Stage	Comprehensive Gain (Loss)	Total Stockholders' Equity (Deficit)
August 15, 2007							
Shares issued for settlement of indebtedness*	0.04	571,429	571	22,286	-	-	22,857
Recognition of value of warrants in settlement of indebtedness				12,349			12,349
Recognition of compensation on option grants							
July 1, 2007		-	-	22,549	-	-	22,549
August 24, 2007		-	-	1,041	-	-	1,041
September 15, 2007		-	-	22,550	-	-	22,550
November 24, 2007		-	-	1,041	-	-	1,041
January 17, 2008		-	-	105,850	-	-	105,850
February 14, 2008		-	-	15,200	-	-	15,200
February 24, 2008		-	-	1,041	-	-	1,041
May 24, 2008		-	-	1,041	-	-	1,041
Comprehensive gain (loss)		-	-	-	-	(3,572)	(3,572)
Net loss for the period		-	-	-	(704,501)	-	(704,501)
<b>Balance, June 30, 2008</b>		43,644,960	\$ 43,645	\$ 2,128,615	\$ (1,901,496)	\$ (885)	\$ 269,880
July 9, 2008							
Shares issued for cash*	0.06	1,666,667	100,000	-	-		100,000
Comprehensive gain (loss)		-	-	-	-	(487)	(487)
Net loss for the period		-	-	-	(122,478)	-	(122,478)
<b>Balance, September 30, 2008</b>		<u>45,311,627</u>	<u>\$ 143,645</u>	<u>\$ 2,128,615</u>	<u>\$ (2,023,974)</u>	<u>\$ (1,372)</u>	<u>\$ 246,914</u>

\*See Note 4(b)

See notes to financial statements.

ANTICUS INTERNATIONAL CORPORATION  
(A COMPANY IN THE DEVELOPMENT STAGE)

Interim Statement of Operations  
(Expressed in U.S. Funds)

	Three Month Period Ended September 30,		Cumulative amounts from date of incorporation (May 1, 2002) Through September 30,
	2008	2007	2008
	(Unaudited)	(Unaudited)	(Unaudited)
Revenue	\$ -	\$ -	\$ -
Operating expense:			
Research and development	1,169	81,361	177,566
Compensation on option grants	-	22,550	244,368
General and administrative expenses	115,526	86,565	1,476,752
Gain on settlement of indebtedness	17	(4,794)	(21,777)
Total operating expenses	(116,712)	(185,682)	(1,876,909)
Other income (expenses):			
Interest income	-	-	2,387
Interest expense	(5,767)	-	(11,763)
Loss from continuing operations	(122,478)	(185,682)	(1,886,284)
Discontinued operations	-	-	(137,690)
Net Loss	\$ (122,478)	\$ (185,682)	\$ (2,023,974)
Other comprehensive loss			
Foreign currency translation adjustment	(487)	-	(1,372)
Net comprehensive loss	<u>\$ (122,965)</u>	<u>\$ (185,682)</u>	<u>\$ (2,025,346)</u>
Basic and diluted net loss per share	<u>\$ (0.00)</u>	<u>\$ (0.00)</u>	
Weighted average common shares outstanding	<u>45,148,583</u>	<u>43,359,246</u>	

See notes to financial statements.

ANTICUS INTERNATIONAL CORPORATION  
(A COMPANY IN THE DEVELOPMENT STAGE)

Interim Statements of Cash Flows  
(Expressed in U.S. Funds)

	Three Month Period Ended September 30,		Cumulative amounts from date of incorporation (May 1, 2002) Through September 30,
	2008	2007	2008
	(Unaudited)	(Unaudited)	(Unaudited)
Cash flows from operating activities:			
Net loss for the period	\$ (122,478)	\$ (185,682)	\$ (2,023,974)
Shares issued for services	-	-	381,848
Shares issued for abandoned license	-	-	76,000
Contributed rent and services	-	-	13,600
Gain on settlement of indebtedness	(487)	(4,794)	(22,281)
Compensation recognized on option grants	-	22,550	271,078
Amortization expense	39,904	37,282	366,312
Depreciation expense	-	-	288
Adjustment to reconcile net loss to net cash used in operating activities			
Decrease (increase) in receivables	(4,540)	(4,290)	(30,016)
Decrease (increase) in prepaid expenses and other assets	(13,455)	3,555	(20,812)
Increase (decrease) in accounts payable and accrued expenses	11,552	(687)	73,173
Increase (decrease) in convertible debentures	4,054	-	8,416
Net cash used in operating activities	<u>(85,450)</u>	<u>(132,066)</u>	<u>(906,368)</u>
Cash flows from investing activities:			
Web site development	-	-	(18,337)
Laboratory equipment	-	-	(3,444)
Net cash used in investing activities	<u>-</u>	<u>-</u>	<u>(21,781)</u>
Cash flows from financing activities:			
Proceeds from issuance of common stock	100,000	-	799,682
Payments in connection with private offering	-	-	(35,984)
Proceeds on issuance of debt	-	-	200,000
Advances received from third party (paid)	-	(550)	-
Net cash used in financing activities	<u>100,000</u>	<u>(550)</u>	<u>963,698</u>
Effect of exchange rates on cash	<u>-</u>	<u>7,625</u>	<u>(1,761)</u>
Net change in cash	14,550	(124,991)	33,788
Cash, beginning of period	<u>19,238</u>	<u>240,952</u>	<u>-</u>
Cash, end of period	<u>\$ 33,788</u>	<u>\$ 115,961</u>	<u>\$ 33,788</u>
Supplemental disclosure with respect to cash flow:			
Cash paid for income taxes	\$ -	\$ -	\$ -
Cash paid for interest	\$ -	\$ -	\$ -

See notes to financial statements.

ANTICUS INTERNATIONAL CORPORATION  
(A COMPANY IN THE DEVELOPMENT STAGE)

NOTES TO INTERIM FINANCIAL STATEMENTS  
SEPTEMBER 30, 2008  
(EXPRESSED IN U.S. FUNDS)  
(UNAUDITED)

---

**1. Basis of presentation**

The accompanying unaudited interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and item 310(b) of Regulation S-B. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended September 30, 2008 are not necessarily indicative of the results that may be expected for the year ended June 30, 2009. The unaudited interim financial statements should be read in conjunction with the financial statements and notes thereto included in the Anticus International Corporation (A Company in the Development Stage) audited financial statements for the year ended June 30, 2008.

**2. Nature of operations**

**a) Organization**

The Company was incorporated in the State of Nevada, U.S.A., on May 1, 2002. On August 19, 2004, the Company effected a 3:1 forward stock split. On November 18, 2004, the Company effected a 3:1 forward stock split. All references in the accompanying financial statements to the number of common shares and per-share amounts have been restated to reflect the forward stock split.

**b) Development stage activities**

The Company is a development stage company as defined in the Statements of Financial Accounting Standards No. 7. The Company is devoting substantially all of its present efforts to establish a new business and none of its planned principal operations have commenced. All losses accumulated since inception has been considered as part of the Company's development stage activities.

The Company continues to develop its business pursuant to its exclusive world-wide license to convert waste materials from beer, soft drink and cheese manufacturers into yeast.

**c) Going concern**

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As shown in the accompanying financial statements, the Company has incurred a net loss of \$2,023,974 for the period from inception, May 1, 2002 to September 30, 2008, and has no sales. The future of the Company is dependent upon its ability to obtain financing and upon future profitable operations. Management has plans to seek additional financing through a public offering of its common stock. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence.

**3. Recent accounting pronouncements**

The FASB issued FSP 133-1 and FIN 45-4, "Disclosures about Credit Derivatives and Certain Guarantees: An Amendment of FASB Statement No. 133 and FASB Interpretation No. 45; and Clarification of the Effective Date of FASB Statement No. 161". This FSP is intended to improve disclosures about credit derivatives by requiring more information about the potential adverse effects of changes in credit risk on the financial position, financial performance and cash flows of the sellers of credit derivatives. In addition, it requires an additional disclosure about the current status of the payment/performance risk of a guarantee. It also clarifies the effective date in FASB Statement No. 161, Disclosures about Derivative Instruments and Hedging Activities. This FSP is effective for reporting periods (annual or interim) ending after November 15, 2008. The adoption of FSP 133-1 and FIN 45-4 did not have a material effect on the company's financial position or results of operations.

ANTICUS INTERNATIONAL CORPORATION  
(A COMPANY IN THE DEVELOPMENT STAGE)

NOTES TO INTERIM FINANCIAL STATEMENTS  
SEPTEMBER 30, 2008  
(EXPRESSED IN U.S. FUNDS)  
(UNAUDITED)

---

#### 4. Capital stock

##### a) Stock split

On August 19, 2004, the Company effected a 3:1 forward stock split. The issued and outstanding common stock after split became 10,050,000. On November 18, 2004, the Company effected a 3:1 forward stock split; the issued and outstanding common stock after the split became 30,150,000. The authorized capital stock remained at 75,000,000 shares.

All references in the accompanying financial statements to the number of common shares and per-share amounts have been restated to reflect the forward stock split.

##### b) Common stock issuances

On July 1, 2005, the Company issued 799,265 shares of its common stock to two of its attorneys and 125,000 shares of its common stock to a consultant. The 924,265 shares were valued at \$138,309.

On July 12, 2005, the Company issued 50,000 shares of its common stock for legal services valued at \$6,000. On July 19, 2005, the Company issued 66,286 shares of its common stock for legal services valued at \$13,257. On July 27, 2005, the Company issued 52,669 shares of its common stock for consulting services valued at \$13,168.

On July 28, 2005, the Company issued 100,000 shares of its common stock in connection with the development of encryption software to be utilized on movies. The shares were valued at \$24,000. The software project subsequently was abandoned. On September 2, 2005, the Company issued 200,000 shares of its common stock in connection with the development of encryption software to be utilized on movies. The shares were valued at \$52,000. The software project subsequently was abandoned.

On September 7, 2005, the Company issued 195,692 shares of its common stock for legal services valued at \$50,880. Also on September 7, 2005, the Company issued 33,180 shares for consulting services valued at \$8,627.

On October 11, 2005, the Company issued 171,872 shares of its common stock for legal services valued at \$29,218. On January 27, 2006, the Company issued 172,765 shares of its common stock for legal services valued at \$14,685. On January 30, 2006, the Company issued 200,000 shares of its common stock for legal services valued at \$18,000. On April 18, 2006, the Company issued 227,500 shares of its common stock for legal services valued at \$40,950.

On April 20, 2006, the Company issued a total of 2,310,000 shares of its common stock for the worldwide exclusive license to the microbiological process known as *Prolactis*. The license was valued at \$462,000.

On May 31, June 12 and June 15, 2006, the Company issued 645,000 shares of its common stock in private offering for \$161,631. On August 14, 2006, the Company issued 75,016 shares of its common stock for legal services valued at \$18,754.

On August 17, 2006, the Company issued 100,000 shares of its common stock in a private offering for \$25,000. On August 21, 2006, the Company issued 125,000 shares of its common stock for legal services valued at \$30,000. On August 31, 2006, the Company issued 60,000 shares of its common stock in a private offering for \$15,000.

On October 3, 2006 the Company issued a total of 1,500,000 shares of its common stock for the waiving of all conditions in the license agreement, giving a clear title to *Prolactis*, valued at \$270,000. On May 28, 2007 the Company issued a total of 5,714,286 shares of its common stock in a private offering for \$400,000 less issue cost of \$12,105.

On August 3, 2007, the Company agreed to issue a total of 571,429 shares of its common stock in settlement of debt totaling \$40,000. The issuance was made on August 15, 2007. The shares were valued at \$22,857. In addition to the issuance of the shares, the Company also granted to the creditor Class A Warrants to purchase 571,429 shares of common stock at a purchase price of \$.12 per share. The warrants expire one year from date of grant. For every warrant exercised, the Company will grant the creditor a Class B Warrant to purchase one share of the Company's common stock at an exercise price of \$.20 per share. The Class B Warrants expire one year from date of grant. The warrants were valued at \$12,349. The Company realized a net gain on the settlement of the debt in the amount of \$4,794.

On June 18, 2008 the Company authorized a private placement to raise \$800,000 through the issuance of a maximum of 13,333,334 common shares at \$0.06 each. Each unit consists of one share of common stock at \$0.06 per share, as well as one warrant exercisable at \$0.12 USD per share no later than July 01, 2009;

In July 2008, the company sold 1,666,667 units of this offering for cash consideration of \$100,000.

ANTICUS INTERNATIONAL CORPORATION  
(A COMPANY IN THE DEVELOPMENT STAGE)

NOTES TO INTERIM FINANCIAL STATEMENTS  
SEPTEMBER 30, 2008  
(EXPRESSED IN U.S. FUNDS)  
(UNAUDITED)

---

**4. Capital stock (Cont'd)**

**c) Stock options**

The Company has a stock option plan under which directors are authorized to grant incentive stock options, to a maximum of four million one hundred seventy-five thousand (4,175,000) of the issued and outstanding shares, to directors, employees and consultants of the Company entitling them to purchase common shares.

Compensation costs attributable to share options granted to employees, directors or consultants is measured at fair value at the grant date and expensed with a corresponding increase to additional paid-in capital.

During the year ended June 30, 2006, a total of 300,000 options were granted to two (2) directors, of which 100,000 were cancelled and reissued under modified terms, as follows: On October 12, 2005, the board approved compensation to PH Vincent consisting of 100,000 options expiring December 31, 2007 at a price of \$0.17 per share; these options were re-priced and reissued to be consistent with the 100,000 options granted at a price of \$0.085 per share to Gilles Varin on January 23, 2006 and expiring on December 31, 2007. On April 19, 2006 each director received an additional 50,000 options at a price of \$0.19 per share expiring December 31, 2007.

On August 30, 2006, the Company agreed to pay Mr. Trudeau compensation of five hundred thousand (500,000) options expiring June 30, 2008, exercisable at US\$0.24, said options to be vested according to the following schedule:

- 125,000 December 15, 2006
- 125,000 March 15, 2007
- 125,000 June 15, 2007
- 125,000 September 15, 2007

On October 3, 2006, the board approved compensation to PH Vincent consisting of 50,000 options expiring December 31, 2007 at a price of \$0.18 per share.

During the year ended June 30, 2007, the recognized compensation expense associated with options granted were valued at \$74,055, which was charged to operations.

On January 17, 2008, the Company agreed to pay administrators and a special advisor compensation of two million nine hundred thousand (2,900,000) options expiring January 17, 2013, exercisable at US\$0.07.

On February 14, 2008, the Company agreed to pay a supplier compensation of four hundred thousand (400,000) options expiring February 28, 2011, exercisable at US\$0.12.

On October 16, 2007, the Company agrees to pay Mr. Trudeau compensation of five hundred thousand (500,000) options expiring June 30, 2009, exercisable at US\$0.07, said options to be vested according to the following schedule:

- 125,000 November 24, 2007
- 125,000 February 24, 2008
- 125,000 May 24, 2008
- 125,000 August 24, 2008

ANTICUS INTERNATIONAL CORPORATION  
(A COMPANY IN THE DEVELOPMENT STAGE)

NOTES TO INTERIM FINANCIAL STATEMENTS  
SEPTEMBER 30, 2008  
(EXPRESSED IN U.S. FUNDS)  
(UNAUDITED)

---

**4. Capital stock (Cont'd)**

During the year ended June 30, 2008, the recognized compensation expense associated with options granted were valued at \$186,639, which was charged to operations.

The following is a summary of the outstanding options:

	<u>Number of shares</u>	<u>Weighted average exercise price</u>
Outstanding June 30, 2006	300,000	0.12
Granted	425,000	0.24
Exercised	-	-
Cancelled	-	-
Outstanding June 30, 2007	725,000	0.19
Granted	3,800,000	0.08
Exercised	-	-
Cancelled	(350,000)	(0.15)
Outstanding June 30, 2008 and September 30, 2008	<u>4,175,000</u>	<u>0.10</u>

All of the outstanding options can be exercised through January 17, 2013 at a price per share ranging from \$0.07 to \$0.24. The fair value of each option granted is estimated at the respective grant date using the Black-Scholes Option Module. Options granted during the year ended June 30, 2008 were valued at \$186,639 which was charged to operations. The following assumptions were made in estimating fair value:

Dividend yield	0%
Expected life	365 to 1 662 days
Risk free interest rate	2.00% to 4.25%
Expected volatility	181% to 350%

**5. Subsequent event**

In November 2008, the company sold 1,666,667 units of the authorized private placement (note 4b)) for a cash consideration of \$100,000.

## **Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations**

This statement may include projections of future results and “forward looking statements” as that term is defined in Section 27A of the Securities Act of 1933 as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934 as amended (the “Exchange Act”). All statements that are included in this Quarterly Report, other than statements of historical fact, are forward looking statements. Although management believes that the expectations reflected in these forward looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.

### **Summary of Operations**

The Company continues to pursue its goals of commercializing the Prolactis™ microbiological process.

On Oct 16, 2007, the Company announced that the demonstration and operating unit of the Quebec science complex has started production of lactic yeast (*Kluyveromyces marxianus*) samples. Green Yeast began distributing these yeast samples to its potential customers and partners, so that they can analyze this yeast themselves, suggest adjustments specific to their needs (e.g., live or inactive yeast, dried or not, according to different drying methods (spray, drum, fluidized bed), suggest adjustments to the nutrient content, etc.), and recognize the product's quality. The objective of this sampling campaign was to show with certainty our ability to produce a quality yeast strain that meets the market's expectations. This phase also had the aim of refining the process to achieve production efficiency.

The demonstration stage has indicated that potential customers being satisfied with the analysis of the small samples provided; require larger samples of up to 500 kilograms to further evaluate the product. The demonstration unit lacked this production capacity.

Anticus is expanding this production capacity by building an expandable production line which will have a bioreactor capable of producing the small 500 kilogram evaluation orders. This line will have all the supporting separators and drying systems and can be expanded by adding additional bioreactors as order levels increase.

The Company has recently reevaluated the capital required to bring a suitable facility into operation and is estimating an additional \$1,400,000 may be required. The Company is looking into ways to reduce this cost by trying to acquire used equipment suitable for our needs and potentially leasing new or used equipment if available.

On January 17, 2008 the Company authorized a private placement to raise Six Hundred Thousand Dollars (\$600 000 USD) through the issuance of non guaranteed convertible debentures (the “Debentures”) in tranches of \$1,000 each, bearing interest at the rate of 8% per year and maturing on the second anniversary of their issuance date, such Debentures to be convertible at the option of the holder into common shares of the Corporation at a price of \$0.08 per common share, subject to the right of the Corporation to force conversion if the common shares trade at a minimum price of \$0.16 per common share for fifteen consecutive trading days. The company may pay a 6 percent commission. The Company sold \$200,000 through this convertible debt financing and no additional placements are being accepted on this offering. The Company was late in paying the accrued interest that was due on September 30, 2008. As of September 30, 2008, none of the amounts owed under the debentures have been converted to equity.

On May 9, 2008 the Company announced that its common shares are again listed on the Over the Counter Bulletin Board under the symbol ATCI.OB.

On June 25, 2008, the Company entered into an agreement with Redal, Inc, to construct a bioreactor capable of the larger sample quantities required. The cost is approximately \$30,000.

On June 18, 2008 the Company authorized a private placement to raise Eight Hundred Thousand Dollars (\$800 000 USD) through the issuance of a maximum of Thirteen Million Three Hundred Thirty-three Thousand and Three Hundred Thirty-four common shares (13,333,334) at \$0.06 USD each. Each unit consists of one share of common stock at \$0.06 USD per share, as well as one warrant exercisable at \$0.12 USD per share no later than July 01, 2009;

In July 2008, the Company sold 1,666,667 units of this offering for \$100,000 USD to a single investor.

In November 2008, the company sold 1,666,667 units of this offering for \$100,000 USD to a single investor.

Contingent upon our financing requirements, we look forward to bringing our pilot plant into operation as soon as possible.

## **Financial Summary**

### Results of Operations for the Three-Months Ended September 30, 2008

The Company reports a net loss of \$122,478 for the three-months ended September 30, 2008 versus a net loss of \$185,682 for the three-month period ending September 30, 2007. The net loss for the three-month period ended September 30, 2008 is primarily comprised of general and administrative expenses of \$115,526. The net loss for the comparable period ending September 30, 2007 is primarily comprised of research and development costs of \$81,361; compensation on option granting totaling \$22,550; and general and administrative expenses of \$86,565.

### Liquidity and Capital Resources

During the three-month period ending September 30, 2008 the Company's cash position increased by \$14,550. Cash used in operating activities totaled \$85,450; and, cash provided by financing activities through a private offering and sell of 1,666,667 shares of common stock was \$100,000.

### Going Concern

Our continuation as a going concern is dependent upon obtaining the additional working capital necessary to sustain our operations. The Company has incurred a net loss of \$2,023,974 for the period from inception, May 1, 2002 to September 30, 2008, and has not generated any revenue since its inception. The future of the Company is dependent upon its ability to obtain financing and upon future profitable operations. Management plans to seek additional financing through the sale of its common stock through private placements. There is no assurance that the Company's current operations will be profitable or the Company will raise sufficient funds to continue operating.

## **Item 3 - Quantitative and Qualitative Disclosures About Market Risk**

Not Applicable

## **Item 4T - Controls and Procedures**

### Evaluation of Disclosure Controls and Procedures

The Company's Chief Executive Officer and Chief Financial Officer, Mr. Trudeau, has evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (the "Exchange Act"). Based on that evaluation, the Company's Chief Executive Officer and Chief Financial Officer has concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that information required to be disclosed in our Exchange Act reports is (1) recorded, processed, summarized and reported in a timely manner, and (2) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Controls

There has been no change in the Company's internal controls over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

Internal control systems, no matter how well designed and operated, have inherent limitations. Therefore, even a system which is determined to be effective cannot provide absolute assurance that all control issues have been detected or prevented. Our systems of internal controls are designed to provide reasonable assurance with respect to financial statement preparation and presentation.

## **Part II OTHER INFORMATION**

### **Item 1 Legal Proceedings**

None, for the period ending September 30, 2008

### **Item 2 Unregistered Sales of Equity Securities and Use of Proceeds**

During the three month period ending September 30, 2008:

On June 18, 2008 the Company authorized a private placement to raise Eight Hundred Thousand Dollars (\$800 000 USD) through the issuance of a maximum of Thirteen Million Three Hundred Thirty-three Thousand and Three Hundred Thirty-four common shares (13,333,334) at \$0.06 USD each. Each unit consists of one share of common stock at \$0.06 USD per share, as well as one warrant exercisable at \$0.12 USD per share no later than July 01, 2009;

In July 2008, the company sold 1,666,667 units of this offering for \$100,000 USD to a single investor.

In November 2008, the company sold 1,666,667 units of this offering for \$100,000 USD to a single investor.

All sales were issued as exempted transactions under Section 4(2) of the Securities Act of 1933, Regulation S and are subject to Rule 144 of the Securities Act of 1933. The recipient(s) of our securities took them for investment purposes without a view to distribution. Furthermore, they had access to information concerning our Company and our business prospects; there was no general solicitation or advertising for the purchase of our securities; and the securities are restricted pursuant to Rule 144.

The company is using these to continue the development of our process. Proceeds are also used to satisfy general operating expenses which include accounting fees and other professional services.

### **Item 3 Defaults Upon Senior Securities**

None, for the period ending September 30, 2008

### **Item 4 Submission of Matters to a Vote of Security Holders**

None, for the period ending September 30, 2008

### **Item 5 Other Information**

None

### **Item 6 Exhibits and Reports**

#### Exhibits

Anticus International Corporation includes herewith the following exhibits:

- 31.1 Certification of Principal Executive Officer (Rule 13a-14(a)/15(d)-14(a))
- 32.1 Certification of Principal Executive Officer (18 U.S.C. 1350)

## SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Anticus International Corporation**

Date: April 22, 2009

By: /s/ Daniel Trudeau, President

Daniel Trudeau, President  
Principal Executive Officer  
Principal Accounting Officer